- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02899767
Transfusion in Adult Acute Myeloid Leukemia
Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukemia
Acute myeloid leukaemia (AML) is a haematological malignant disease characterized by an uncontrolled proliferation of immature hematopoietic cells. Over the last two decades, clinical trials have demonstrated an improved response rate in younger adult AML. Aggressive induction plus more potent intensification programs with chemotherapy alone or chemotherapy plus stem cell transplantation (SCT) has improved treatment results. Advances in understanding disease biology, improvements in induction and consolidation program, and better supportive care have also all contributed. A number of clinical and laboratory characteristics influence the response to treatment and, thus, the survival of patients with AML. Among them, cytogenetic at diagnosis represents the most important prognostic variable. However, other factors may have a prognostic value and may influence patient's outcome.
Anaemia and thrombocytopenia are cardinal manifestations of AML. Over the last decades, it has become apparent that the frequency of allogeneic blood transfusions can modify host immunity and clinical outcomes. Anaemia has long been recognized as an adverse prognostic factor in myelodysplastic syndrome (MDS), which represents a pre-leukemic disease. Red blood cell (RBC) transfusion need was identified as a strong and independent risk factor for survival in MDS, for which the presence and severity of anaemia were attributed to a clonally advanced and biologically more aggressive disease.
Based on these data, we retrospectively assessed the prognostic value of RBC and platelet transfusions at the time of diagnosis and the frequency of transfusions during the first induction course of chemotherapy in a large unselected group of patients with previously untreated AML.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patient > 15 years old
- Newly diagnosed AML or post myelodysplastic syndrome (MDS)
Exclusion Criteria:
- Patients with M3 AML of FAB classification (APL, Acute Promyelocytic Leukemia)
- World Health Organization (WHO) performance status >2;
- Left ventricular systolic ejection fraction below the normal range
- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
- Serum creatinine concentration > 2x ULN (Upper Limit of Normal laboratory ranges),
- AST or ALT levels > 2.0 x ULN, except if AML-related
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall survival (OS)
Tidsram: 3 year OS
|
Overall survival (OS) is defined as the time elapsed between induction chemotherapy regimen and death for any cause.
Patients not known to have this event are censored on the date they were last examined
|
3 year OS
|
Overall survival (OS)
Tidsram: 7 year OS
|
Overall survival (OS) is defined as the time elapsed between induction chemotherapy regimen and death for any cause.
Patients not known to have this event are censored on the date they were last examined
|
7 year OS
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Complete remission (CR) rate
Tidsram: Up to 10 weeks
|
Response to induction therapy was assessed after one or two courses of chemotherapy.
CR was defined according to standard criteria as less than 5 % blasts in bone marrow aspirates with evidence of maturation of cell lines and restoration of peripheral blood counts
|
Up to 10 weeks
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 69HCL16_0562
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Akut myeloid leukemi
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Oryzon Genomics S.A.RekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärFörenta staterna
-
University Hospital, AntwerpRekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärBelgien
-
Medical College of WisconsinRekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärFörenta staterna
-
Centre Leon BerardNETRIS PharmaRekryteringAkut myeloid leukemi refraktärFrankrike
-
Servier Affaires MédicalesRekryteringAkut myeloid leukemi (AML)Nederländerna, Italien, Österrike, Frankrike
-
Moleculin Biotech, Inc.RekryteringLeukemi, Myeloid, AkutItalien, Polen
-
Polaris GroupRekryteringAkut myeloid leukemi, vuxenFörenta staterna
-
The First Affiliated Hospital of Soochow UniversityRekryteringAkut myeloid leukemi, vuxenKina
-
PETHEMA FoundationRekrytering